Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: EUCTR 2006-003080-31. We help you review the study, but cannot decide medical eligibility.
Not recruitingEUCTR 2006-003080-31
A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
SchizophreniaDrug
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Check recruitment and locations
Historical registry record checked by HopeStage on . Registry information can change. Always confirm availability with the research team.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
View the historical EU CTR record
Historical EU CTR country statuses
No specific site is confirmed in the available information. Check the official source for locations and remote participation.
Key information made simple
What the source confirms
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
What should you check before joining?
Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.
Your next step
Participation locations and format are not confirmed in the available information. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 180
- Sponsor
- NV Organon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France, Austria, Czechia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-003080-31
- Official title
- A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a...
- Official source
- Official registry link
Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: EUCTR 2006-003080-31. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Confirm the location and whether remote participation is possible with the research team.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What does the official source confirm?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Is this study recruiting?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
How can I check the participation requirements?
Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Not recruitingEUCTR 2008-002676-10
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Not recruitingEUCTR 2008-002699-83
A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Not recruitingEUCTR 2017-001459-30
A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.